#United States #San Diego #Consano Bio #C-1101 #Chronic Sciatica

Consano Bio to Present New Treatment at 2026 BIO International Convention

Consano Bio, a pioneering biotechnology company focused on innovative therapies for severe pain conditions, is scheduled to present at the upcoming BIO International Convention, taking place from June 22-25, 2026, in San Diego, California. The CEO, Andrew Hall, will lead a detailed discussion to unveil the company's latest advancements in treating chronic sciatica with their innovative therapy, C-1101.

C-1101 is positioned as a potential first-in-class, non-opioid solution aimed at addressing chronic sciatica, a condition that affects many individuals and can significantly hinder quality of life. This multi-protein therapeutic is developed to be delivered directly to the area of nerve injury, targeting not just the symptoms but the underlying biological factors causing persistent pain.

Event Details

• - Event Name: 2026 BIO International Convention
• - Date & Time: Monday, June 22, at 3:30 PM
• - Venue: San Diego Convention Center, Theater 1
• - Presenter: Andrew Hall, CEO of Consano Bio

During the convention, attendees can expect Mr. Hall to engage in one-on-one sessions with investors and potential partners, where he will elaborate on the company's strategic business and clinical development plans, along with crucial milestones they anticipate achieving.

About the Clinical Trial

Consano Bio has initiated a Phase 1 clinical trial for C-1101 (referred to as C-1101-101, NCT07264270), which focuses on patients suffering from painful lumbosacral radiculopathy, commonly known as chronic sciatica. This trial marks a significant step forward in exploring targeted biological therapies that aim to modify disease progression rather than merely alleviate symptoms.

C-1101 leverages a unique formulation derived from platelets, allowing for localized delivery to afflicted nerve sites. By concentrating on the inflammatory processes associated with nerve damage, Consano Bio aims to provide a comprehensive approach to treating this debilitating condition.

Vision for the Future

Founded in 2023 and headquartered in the Greater Boston area, Consano Bio is committed to revolutionizing the treatment landscape for orthopedic and painful conditions through its innovative biologics. Their ongoing efforts emphasize a patient-centered approach which could redefine management options for individuals affected by chronic pain.

Attendees of the BIO International Convention will gain insights into how C-1101 represents a significant leap in non-opioid treatment alternatives for chronic pain, encouraging a conversation about the future of pain management rooted in biological innovation. For those interested in learning more about Consano Bio and their developments, visit their official website at www.consanobio.com.

Conclusion

As the 2026 BIO International Convention approaches, anticipation builds around Consano Bio's contributions to advancing therapeutic options for chronic sciatica. The potential impact of C-1101 could provide hope for countless individuals seeking relief from incapacitating pain. With the biotechnology sector continuously evolving, events like this highlight the importance of innovation in addressing complex health challenges.